Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients

Chigusa Morizane(Tokyo National Hospital), Tomohiro Yamaguchi(Japanese Foundation For Cancer Research), Masafumi Ikeda(National Cancer Center Hospital East), Yasushi Kojima(Center for Global Health), Kohei Nakachi(National Cancer Center Hospital East), Makoto Ueno(Kanagawa Prefectural Hospital Organization), Shuichi Mitsunaga(National Cancer Center Hospital East), Junji Furuse(Kanagawa Prefectural Hospital Organization), Takuji Okusaka(National Cancer Centre Japan), Eiichiro Suzuki(Kyorin University), Shunsuke Kondo(University of Hawaiʻi at Mānoa), Hideki Ueno
Cancer Chemotherapy and Pharmacology
November 25, 2011
10.1007/s00280-011-1786-6
Cited by 8

Related Papers

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective
|The Oncologist|2010|977
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
|Nature Genetics|2014|780